PL324240A1 - Derivatives of azetidinone for treating atherosclerosis - Google Patents
Derivatives of azetidinone for treating atherosclerosisInfo
- Publication number
- PL324240A1 PL324240A1 PL96324240A PL32424096A PL324240A1 PL 324240 A1 PL324240 A1 PL 324240A1 PL 96324240 A PL96324240 A PL 96324240A PL 32424096 A PL32424096 A PL 32424096A PL 324240 A1 PL324240 A1 PL 324240A1
- Authority
- PL
- Poland
- Prior art keywords
- azetidinone
- derivatives
- treating atherosclerosis
- atherosclerosis
- treating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
- C07D205/085—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a nitrogen atom directly attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
- C07D205/09—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a sulfur atom directly attached in position 4
- C07D205/095—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a sulfur atom directly attached in position 4 and with a nitrogen atom directly attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9513442.5A GB9513442D0 (en) | 1995-07-01 | 1995-07-01 | Novel compounds |
| GBGB9515056.1A GB9515056D0 (en) | 1995-07-22 | 1995-07-22 | Novel compounds |
| GBGB9515206.2A GB9515206D0 (en) | 1995-07-25 | 1995-07-25 | Novel compounds |
| GBGB9516985.0A GB9516985D0 (en) | 1995-08-18 | 1995-08-18 | Novel compounds |
| GBGB9525132.8A GB9525132D0 (en) | 1995-12-08 | 1995-12-08 | Novel compounds |
| GBGB9608650.9A GB9608650D0 (en) | 1996-04-26 | 1996-04-26 | Novel compounds |
| GBGB9608651.7A GB9608651D0 (en) | 1996-04-26 | 1996-04-26 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL324240A1 true PL324240A1 (en) | 1998-05-11 |
Family
ID=27562921
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL96324240A PL324240A1 (en) | 1995-07-01 | 1996-06-20 | Derivatives of azetidinone for treating atherosclerosis |
Country Status (23)
| Country | Link |
|---|---|
| EP (1) | EP0840725A1 (xx) |
| JP (1) | JP2002515852A (xx) |
| KR (1) | KR19990028630A (xx) |
| CN (1) | CN1197452A (xx) |
| AP (1) | AP728A (xx) |
| AU (1) | AU708032B2 (xx) |
| BG (1) | BG102214A (xx) |
| BR (1) | BR9609445A (xx) |
| CA (1) | CA2225627A1 (xx) |
| CZ (1) | CZ422197A3 (xx) |
| EA (1) | EA199800109A1 (xx) |
| HU (1) | HUP9901153A3 (xx) |
| IL (1) | IL122650A0 (xx) |
| MA (1) | MA23922A1 (xx) |
| MX (1) | MX9800186A (xx) |
| NO (1) | NO976158L (xx) |
| NZ (1) | NZ311684A (xx) |
| OA (1) | OA10648A (xx) |
| PE (1) | PE8998A1 (xx) |
| PL (1) | PL324240A1 (xx) |
| SK (1) | SK178497A3 (xx) |
| TR (1) | TR199701762T1 (xx) |
| WO (1) | WO1997002242A1 (xx) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000502079A (ja) * | 1995-12-08 | 2000-02-22 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | アテローム性動脈硬化症の治療のための単環β―ラクタム誘導体 |
| BR9709196A (pt) * | 1996-04-26 | 1999-05-25 | Smithkline Beecham Plc | Derivados de azetidinona para o tratamento de aterosclerose |
| GB9608649D0 (en) * | 1996-04-26 | 1996-07-03 | Smithkline Beecham Plc | Novel compounds |
| WO2001060805A1 (en) | 2000-02-16 | 2001-08-23 | Smithkline Beecham P.L.C. | Pyrimidine-4-one derivatives as ldl-pla2 inhibitors |
| GB0024808D0 (en) | 2000-10-10 | 2000-11-22 | Smithkline Beecham Plc | Novel compounds |
| KR101461659B1 (ko) | 2007-05-11 | 2014-11-17 | 토마스 제퍼슨 유니버시티 | 신경변성 질환 및 장애의 치료 및 예방 방법 |
| WO2008141176A1 (en) | 2007-05-11 | 2008-11-20 | The Trustees Of The University Of Pennsylvania | Methods of treatment of skin ulcers |
| US8962633B2 (en) | 2007-05-11 | 2015-02-24 | Thomas Jefferson University | Methods of treatment and prevention of metabolic bone diseases and disorders |
| JP5886310B2 (ja) | 2010-12-06 | 2016-03-16 | グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ | Ｌｐ−ＰＬＡ２により媒介される疾患または状態の処置における使用のためのピリミジノン化合物 |
| EP2651403B1 (en) | 2010-12-17 | 2020-12-02 | Glaxo Group Limited | Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases |
| CN103619831B (zh) | 2011-06-27 | 2016-05-04 | 中国科学院上海药物研究所 | 唑类杂环化合物、其制备方法、药物组合物和用途 |
| BR112014001665A2 (pt) | 2011-07-27 | 2017-02-14 | Glaxo Group Ltd | compostos de 2,3-di-hidroimidazo[1,2-c]pirimidin-5(1h)-ona utilizados como inibidores de lp-plaz |
| RU2014107486A (ru) | 2011-07-27 | 2015-09-10 | Глэксо Груп Лимитед | Бициклические пиримидоновые соединения |
| JP2016505053A (ja) | 2013-01-25 | 2016-02-18 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｌｐ‐ＰＬＡ２の阻害剤としての二環式ピリミドン化合物 |
| UY35276A (es) | 2013-01-25 | 2014-08-29 | Glaxosmithkline Ip Dev Ltd | Nuevos compuestos que inhiben la actividad de Lp-PLA2 |
| WO2014114248A1 (en) | 2013-01-25 | 2014-07-31 | Glaxosmithkline Intellectual Property Development Limited | Compounds |
| WO2016012916A1 (en) | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2 |
| WO2016012917A1 (en) | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2 |
| CN112778331B (zh) | 2019-11-09 | 2022-07-05 | 上海赛默罗生物科技有限公司 | 三环二氢咪唑并嘧啶酮衍生物、其制备方法、药物组合物和用途 |
| CN115304620A (zh) | 2021-05-07 | 2022-11-08 | 上海赛默罗生物科技有限公司 | 嘧啶酮衍生物、其制备方法、药物组合物和用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4680391A (en) * | 1983-12-01 | 1987-07-14 | Merck & Co., Inc. | Substituted azetidinones as anti-inflammatory and antidegenerative agents |
| IL89835A0 (en) * | 1988-04-11 | 1989-12-15 | Merck & Co Inc | Substituted azetidinones,their preparation and pharmaceutical compositions containing them |
| IL99658A0 (en) * | 1990-10-15 | 1992-08-18 | Merck & Co Inc | Substituted azetidinones and pharmaceutical compositions containing them |
| GB9421816D0 (en) * | 1994-10-29 | 1994-12-14 | Smithkline Beecham Plc | Novel compounds |
| PL320937A1 (en) * | 1994-12-22 | 1997-11-10 | Smithkline Beecham Plc | Substituted azetidin-2-ones for treating arterial atheromatosis |
-
1996
- 1996-06-20 PL PL96324240A patent/PL324240A1/xx unknown
- 1996-06-20 NZ NZ311684A patent/NZ311684A/xx unknown
- 1996-06-20 CA CA002225627A patent/CA2225627A1/en not_active Abandoned
- 1996-06-20 AU AU63050/96A patent/AU708032B2/en not_active Ceased
- 1996-06-20 HU HU9901153A patent/HUP9901153A3/hu unknown
- 1996-06-20 SK SK1784-97A patent/SK178497A3/sk unknown
- 1996-06-20 JP JP50477297A patent/JP2002515852A/ja active Pending
- 1996-06-20 WO PCT/EP1996/002765 patent/WO1997002242A1/en not_active Application Discontinuation
- 1996-06-20 TR TR97/01762T patent/TR199701762T1/xx unknown
- 1996-06-20 BR BR9609445A patent/BR9609445A/pt unknown
- 1996-06-20 CZ CZ974221A patent/CZ422197A3/cs unknown
- 1996-06-20 KR KR1019970709952A patent/KR19990028630A/ko not_active Application Discontinuation
- 1996-06-20 CN CN96196661A patent/CN1197452A/zh active Pending
- 1996-06-20 AP APAP/P/1997/001161A patent/AP728A/en active
- 1996-06-20 EA EA199800109A patent/EA199800109A1/ru unknown
- 1996-06-20 EP EP96922030A patent/EP0840725A1/en not_active Withdrawn
- 1996-06-20 IL IL12265096A patent/IL122650A0/xx unknown
- 1996-06-28 PE PE1996000496A patent/PE8998A1/es not_active Application Discontinuation
- 1996-06-28 MA MA24298A patent/MA23922A1/fr unknown
-
1997
- 1997-12-30 NO NO976158A patent/NO976158L/no unknown
- 1997-12-31 OA OA70172A patent/OA10648A/en unknown
-
1998
- 1998-01-07 MX MX9800186A patent/MX9800186A/es unknown
- 1998-01-28 BG BG102214A patent/BG102214A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO976158L (no) | 1998-02-25 |
| SK178497A3 (en) | 1998-07-08 |
| JP2002515852A (ja) | 2002-05-28 |
| EP0840725A1 (en) | 1998-05-13 |
| WO1997002242A1 (en) | 1997-01-23 |
| BG102214A (en) | 1998-08-31 |
| CN1197452A (zh) | 1998-10-28 |
| AU708032B2 (en) | 1999-07-29 |
| EA199800109A1 (ru) | 1998-10-29 |
| HUP9901153A2 (hu) | 1999-08-30 |
| AU6305096A (en) | 1997-02-05 |
| HUP9901153A3 (en) | 1999-11-29 |
| PE8998A1 (es) | 1998-03-20 |
| KR19990028630A (ko) | 1999-04-15 |
| CA2225627A1 (en) | 1997-01-23 |
| NO976158D0 (no) | 1997-12-30 |
| CZ422197A3 (cs) | 1998-06-17 |
| BR9609445A (pt) | 1999-04-06 |
| IL122650A0 (en) | 1998-08-16 |
| TR199701762T1 (xx) | 1998-05-21 |
| MA23922A1 (fr) | 1996-12-31 |
| AP9701161A0 (en) | 1998-01-31 |
| MX9800186A (es) | 1998-07-31 |
| OA10648A (en) | 2002-09-25 |
| AP728A (en) | 1999-01-29 |
| NZ311684A (en) | 2000-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL324240A1 (en) | Derivatives of azetidinone for treating atherosclerosis | |
| ZA959100B (en) | Azetidinone derivatives for the treatment of atherosclerosis | |
| AU4389896A (en) | Substituted azetidin-2-ones for treatment of atherosclerosis | |
| ZA965088B (en) | Methods of preventing or treating allergles | |
| AU4518897A (en) | Method of treating atherosclerosis | |
| PL321263A1 (en) | Derivatives of indole useful in treating osteoporosis | |
| PL324451A1 (en) | Derivatives of diphenylmethylenepiperidine | |
| IL126696A0 (en) | Azetidinone derivatives for the treatment of atherosclerosis | |
| PL314674A1 (en) | Method of purifying melamine | |
| AU5737996A (en) | Method of reducing malodor | |
| PL327600A1 (en) | Method of treating depressions | |
| GB9611614D0 (en) | Process for inhibiting the effect of flourescent whitening agents | |
| AU2051397A (en) | Method of treating alopecia | |
| HUP9900138A3 (en) | Method for treatment of wood element | |
| GB9602162D0 (en) | Treatment of waste | |
| GB9517933D0 (en) | Method of treating laundry | |
| AU7113996A (en) | Methods of treating beta-amyloid-associated conditions | |
| ZA98726B (en) | Method of treating pulp | |
| GB9507825D0 (en) | Method of treatment | |
| ZA968320B (en) | Treatment of atherosclerosis | |
| PL335904A1 (en) | Application of 7alpha-methyl-17alpha-ethynylestrane derivative for treating arteriosclerosis | |
| PL326251A1 (en) | Method of treating tobacco | |
| LT95123A (en) | Diaprojector for investigating of microobjectives | |
| FI104333B1 (fi) | Menetelmä massan käsittelemiseksi | |
| GB9502514D0 (en) | Method of treatment |